Targeted treatment of differentiated and medullary thyroid cancer

Journal of Thyroid Research

Volumn 2011, Issue , 2011, Pages

  Bales, Shannon R ^a   Chopra, Inder J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; B RAF KINASE; CABOZANTINIB; CALCITONIN; EXELIXIS; GLUTAMIC ACID; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MOTESANIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN RET; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VEMURAFENIB; WITHAFERIN A; XL 281;

ADVANCED CANCER; ADVERSE DRUG REACTION; BREAST CANCER; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; DIARRHEA; DIFFERENTIATED THYROID CANCER; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FAMILIAL CANCER; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOPIGMENTATION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULAR BIOLOGY; NAUSEA; NONHUMAN; OVARY CANCER; PALMAR PLANTAR ERYTHRODESIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QT PROLONGATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CARCINOMA; STOMATITIS; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

EID: 84872221734     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.4061/2011/102636     Document Type: Review

References (133)

1. "Surveillance, Epidemiology, and End Results (S. E. E. R. Program)", Generate custom reports from the cancer statistics review, Seer 9:1975-2007, December 2010, http://seer.cancer.gov/.
2. M. J. Schlumberger, "Papillary and follicular thyroid carcinoma", New England Journal of Medicine, vol. 338, no. 5, pp. 297-306, 1998. (Pubitemid 28065257)
3. M. R. Castro, E. R. Bergert, J. R. Goellner, I. D. Hay, and J. C. Morris, "Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake", Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 11, pp. 5627-5632, 2001. (Pubitemid 33070298)
4. L. S. Ward, P. L. Santarosa, F. Granja, L. V. M. Da Assumpçã o, M. Savoldi, and G. H. Goldman, "Low expression of sodium iodide symporter identifies aggressive thyroid tumors", Cancer Letters, vol. 200, no. 1, pp. 85-91, 2003. (Pubitemid 37222362)
5. J. A. Fagin, "How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy", Journal of Endocrinology, vol. 183, no. 2, pp. 249-256, 2004. (Pubitemid 39562707)
6. C. Scollo, E. Baudin, J. P. Travagli et al., "Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 2070-2075, 2003. (Pubitemid 36549878)
7. S. I. Sherman, "Cytotoxic chemotherapy for differentiated thyroid carcinoma", Clinical Oncology, vol. 22, no. 6, pp. 464-468, 2010.
8. M. Xing, "BRAF mutation in thyroid cancer", Endocrine-Related Cancer, vol. 12, no. 2, pp. 245-262, 2005. (Pubitemid 40896444)
9. G. Salvatore, V. De Falco, P. Salerno et al., "BRAF is a therapeutic target in aggressive thyroid carcinoma", Clinical Cancer Research, vol. 12, no. 5, pp. 1623-1629, 2006.
10. B. Ouyang, J. A. Knauf, E. P. Smith et al., "Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo", Clinical Cancer Research, vol. 12, no. 6, pp. 1785-1793, 2006.
11. P. Hou, E. Bojdani, and M. Xing, "Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 2, pp. 820-828, 2010.
12. D. J. Lim, K. H. Baek, Y. S. Lee et al., "Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma", Thyroid, vol. 17, no. 9, pp. 883-888, 2007.
13. E. T. Kimura, M. N. Nikiforova, Z. Zhu, J. A. Knauf, Y. E. Nikiforov, and J. A. Fagin, "High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma", Cancer Research, vol. 63, no. 7, pp. 1454-1457, 2003. (Pubitemid 36373628)
14. P. T. C. Wan, M. J. Garnett, S. M. Roe et al., "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF", Cell, vol. 116, no. 6, pp. 855-867, 2004. (Pubitemid 38410730)
15. P. Hou, D. Liu, Y. Shan et al., "Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer", Clinical Cancer Research, vol. 13, no. 4, pp. 1161-1170, 2007. (Pubitemid 46424056)
16. M. Santoro, N. A. Dathan, M. T. Berlingieri et al., "Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma", Oncogene, vol. 9, no. 2, pp. 509-516, 1994. (Pubitemid 24041530)
17. Y. E. Nikiforov, J. M. Rowland, K. E. Bove, H. Monforte-Munoz, and J. A. Fagin, "Distinct pattern of ret oncogene rearrangements in morphological variants of radiationinduced and sporadic thyroid papillary carcinomas in children", Cancer Research, vol. 57, no. 9, pp. 1690-1694, 1997. (Pubitemid 27199660)
18. G. Tallini, M. Santoro, M. Helie et al., "RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes", Clinical Cancer Research, vol. 4, no. 2, pp. 287-294, 1998. (Pubitemid 28122740)
19. M. D. Ringel, N. Hayre, J. Saito et al., "Overexpression and overactivation of Akt in thyroid carcinoma", Cancer Research, vol. 61, no. 16, pp. 6105-6111, 2001. (Pubitemid 32762546)
20. H. Sun, R. Lesche, D. M. Li et al., "PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3, 4, 5, -trisphosphate and Akt/protein kinase B signaling pathway", Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 11, pp. 6199-6204, 1999. (Pubitemid 29256643)
21. R. Ciampi and Y. E. Nikiforov, "Minireview: RET/PTC rearrangements and braf mutations in thyroid tumorigenesis", Endocrinology, vol. 148, no. 3, pp. 936-941, 2007.
22. Y. Cohen, M. Xing, E. Mambo et al., "BRAF mutation in papillary thyroid carcinoma", Journal of the National Cancer Institute, vol. 95, no. 8, pp. 625-627, 2003. (Pubitemid 36553510)
23. E. Puxeddu, S. Moretti, R. Elisei et al., "BRAFV599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas", Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2414-2420, 2004. (Pubitemid 38619884)
24. R. Elisei, C. Ugolini, D. Viola et al., "BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study", Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 10, pp. 3943-3949, 2008.
25. A. M. Costa, A. Herrero, M. F. Fresno et al., "BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma", Clinical Endocrinology, vol. 68, no. 4, pp. 618-634, 2008. (Pubitemid 351388702)
26. H. Davies, G. R. Bignell, C. Cox et al., "Mutations of the BRAF gene in human cancer", Nature, vol. 417, no. 6892, pp. 949-954, 2002. (Pubitemid 34716871)
27. T. Brummer, H. Naegele, M. Reth, and Y. Misawa, "Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf", Oncogene, vol. 22, no. 55, pp. 8823-8834, 2003. (Pubitemid 38021498)
28. R. Ciampi, J. A. Knauf, R. Kerler et al., "Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer", Journal of Clinical Investigation, vol. 115, no. 1, pp. 94-101, 2005. (Pubitemid 40385509)
29. M. N. Nikiforova, R. Ciampi, G. Salvatore et al., "Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas", Cancer Letters, vol. 209, no. 1, pp. 1-6, 2004. (Pubitemid 38656111)
30. B. J. Collins, A. B. Schneider, R. A. Prinz, and X. Xu, "Low frequency of BRAF mutations in adult patients with papillary thyroid cancers following childhood radiation exposure", Thyroid, vol. 16, no. 1, pp. 61-66, 2006. (Pubitemid 43346505)
31. M. Xing, W. H. Westra, R. P. Tufano et al., "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 12, pp. 6373-6379, 2005. (Pubitemid 41759286)
32. M. N. Nikiforova, E. T. Kimura, M. Gandhi et al., "BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 11, pp. 5399-5404, 2003. (Pubitemid 37452745)
33. A. J. Adeniran, Z. Zhu, M. Gandhi et al., "Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas", American Journal of Surgical Pathology, vol. 30, no. 2, pp. 216-222, 2006. (Pubitemid 43740191)
34. I. Sedliarou, V. Saenko, D. Lantsov et al., "The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma", International journal of oncology, vol. 25, no. 6, pp. 1729-1735, 2004.
35. X. Lee, M. Gao, Y. Ji et al., "Analysis of differential BRAFV600E mutational status in high aggressive papillary thyroid microcarcinoma", Annals of Surgical Oncology, vol. 16, no. 2, pp. 240-245, 2009.
36. M. Frattini, C. Ferrario, P. Bressan et al., "Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer", Oncogene, vol. 23, no. 44, pp. 7436-7440, 2004. (Pubitemid 39382146)
37. P. Soares, V. Trovisco, A. S. Rocha et al., "BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC", Oncogene, vol. 22, no. 29, pp. 4578-4580, 2003. (Pubitemid 36920701)
38. R. M. Quiros, H. G. Ding, P. Gattuso, R. A. Prinz, and X. Xu, "Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations", Cancer, vol. 103, no. 11, pp. 2261-2268, 2005. (Pubitemid 40686569)
39. C. Durante, E. Puxeddu, E. Ferretti et al., "Brief report: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism", Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2840-2843, 2007. (Pubitemid 47037399)
40. D. Liu, S. Hu, P. Hou, D. Jiang, S. Condouris, and M. Xing, "Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant", Clinical Cancer Research, vol. 13, no. 4, pp. 1341-1349, 2007. (Pubitemid 46424076)
41. G. Riesco-Eizaguirre, I. Rodríguez, A. De La Vieja et al., "The BRAFV600E oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer", Cancer Research, vol. 69, no. 21, pp. 8317-8325, 2009.
42. J. A. Fagin, K. Matsuo, A. Karmakar, Dan Lin Chen, S. H. Tang, and H. P. Koeffler, "High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas", Journal of Clinical Investigation, vol. 91, no. 1, pp. 179-184, 1993. (Pubitemid 23037270)
43. L. Ludwig, H. Kessler, M. Wagner et al., "Nuclear factor-?B is constitutively active in C-cell carcinoma and required for RET-induced transformation", Cancer Research, vol. 61, no. 11, pp. 4526-4535, 2001. (Pubitemid 32685784)
44. A. Bounacer, R. Wicker, B. Caillou et al., "High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation", Oncogene, vol. 15, no. 11, pp. 1263-1273, 1997. (Pubitemid 27429741)
45. C. L. Fenton, Y. Lukes, D. Nicholson, C. A. Dinauer, G. L. Francis, and R. M. Tuttle, "The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults", Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1170-1175, 2000. (Pubitemid 32269367)
46. T. Mizuno, K. S. Iwamoto, S. Kyoizumi et al., "Preferential induction of RET/PTC1 rearrangement by X-ray irradiation", Oncogene, vol. 19, no. 3, pp. 438-443, 2000. (Pubitemid 30077345)
47. A. Wirtschafter, R. Schmidt, D. Rosen et al., "Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis", Laryngoscope, vol. 107, no. 1, pp. 95-100, 1997. (Pubitemid 27045201)
48. O. M. Sheils, J. J. O'Leary, V. Uhlmann, K. Lüttich, and E. C. Sweeney, "ret/PTC-1 activation in Hashimoto thyroiditis", International Journal of Surgical Pathology, vol. 8, no. 3, pp. 185-189, 2000.
49. M. N. Nikiforova, C. M. Caudill, P. Biddinger, and Y. E. Nikiforov, "Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas", International Journal of Surgical Pathology, vol. 10, no. 1, pp. 15-22, 2002. (Pubitemid 34245954)
50. N. Ferrara and R. S. Kerbel, "Angiogenesis as a therapeutic target", Nature, vol. 438, no. 7070, pp. 967-974, 2005. (Pubitemid 43093963)
51. M. Klein, J. M. Vignaud, V. Hennequin et al., "Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma", Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 656-658, 2001. (Pubitemid 32207476)
52. C. M. Lennard, A. Patel, J. Wilson et al., "Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer", Surgery, vol. 129, no. 5, pp. 552-558, 2001. (Pubitemid 32374986)
53. A. K. Ghosh, I. Grigorieva, R. Steele, R. G. Hoover, and R. B. Ray, "PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation", Gene, vol. 235, no. 1-2, pp. 85-91, 1999. (Pubitemid 29327286)
54. M. Tamura, J. Gu, E. H. J. Danen, T. Takino, S. Miyamoto, and K. M. Yamada, "PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway", Journal of Biological Chemistry, vol. 274, no. 29, pp. 20693-20703, 1999.
55. P. A. Steck, M. A. Pershouse, S. A. Jasser et al., "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers", Nature Genetics, vol. 15, no. 4, pp. 356-362, 1997. (Pubitemid 27147102)
56. D. S. Byun, K. Cho, B. K. Ryu et al., "Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma", International Journal of Cancer, vol. 104, no. 3, pp. 318-327, 2003. (Pubitemid 36249814)
57. T. Kimura, A. Suzuki, Y. Fujita et al., "Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production", Development, vol. 130, no. 8, pp. 1691-1700, 2003. (Pubitemid 36527527)
58. S. Wang, A. J. Garcia, M. Wu, D. A. Lawson, O. N. Witte, and H. Wu, "Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation", Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1480-1485, 2006. (Pubitemid 43191191)
59. A. Yokomizo, D. J. Tindall, L. Hartmann, R. B. Jenkins, D. I. Smith, and W. Liu, "Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer", International Journal of Oncology, vol. 13, no. 1, pp. 101-105, 1998. (Pubitemid 28267502)
60. M. E. McMenamin, P. Soung, S. Perera, I. Kaplan, M. Loda, and W. R. Sellers, "Loss of PTEN expression in paraffinembedded primary prostate cancer correlates with high Gleason score and advanced stage", Cancer Research, vol. 59, no. 17, pp. 4291-4296, 1999. (Pubitemid 29418745)
61. P. Hou, M. Ji, and M. Xing, "Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors", Cancer, vol. 113, no. 9, pp. 2440-2447, 2008.
62. P. Hou, D. Liu, Y. Shan et al., "Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer", Clinical Cancer Research, vol. 13, no. 4, pp. 1161-1170, 2007. (Pubitemid 46424056)
63. S. M. Wilhelm, C. Carter, L. Tang et al., "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis", Cancer Research, vol. 64, no. 19, pp. 7099-7109, 2004. (Pubitemid 39331023)
64. Y. C. Henderson, S. H. Ann, Y. Kang, and G. L. Clayman, "Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement", Clinical Cancer Research, vol. 14, no. 15, pp. 4908-4914, 2008.
65. D. Strumberg, J. W. Clark, A. Awada et al., "Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors", Oncologist, vol. 12, no. 4, pp. 426-437, 2007. (Pubitemid 46698720)
66. V. Gupta-Abramson, A. B. Troxel, A. Nellore et al., "Phase II trial of sorafenib in advanced thyroid cancer", Journal of Clinical Oncology, vol. 26, no. 29, pp. 4714-4719, 2008.
67. R. T. Kloos, M. D. Ringel, M. V. Knopp et al., "Phase II trial of sorafenib in metastatic thyroid cancer", Journal of Clinical Oncology, vol. 27, no. 10, pp. 1675-1684, 2009.
68. H. Hoftijzer, K. A. Heemstra, H. Morreau et al., "Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma", European Journal of Endocrinology, vol. 161, no. 6, pp. 923-931, 2009.
69. M. E. Cabanillas, S. G. Waguespack, Y. Bronstein et al., "Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2588-2595, 2010.
70. E. T. Lam, M. D. Ringel, R. T. Kloos et al., "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer", Journal of Clinical Oncology, vol. 28, no. 14, pp. 2323-2330, 2010.
71. M. Schmidinger, C. C. Zielinski, U. M. Vogl et al., "Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma", Journal of Clinical Oncology, vol. 26, no. 32, pp. 5204-5212, 2008.
72. Y. Arima, S. Oshima, K. Noda et al., "Sorafenib-induced acute myocardial infarction due to coronary artery spasm", Journal of Cardiology, vol. 54, no. 3, pp. 512-515, 2009.
73. J. P. Arnault, J. Wechsler, B. Escudier et al., "Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib", Journal of Clinical Oncology, vol. 27, no. 23, pp. e59-e61, 2009.
74. G. Bollag, P. Hirth, J. Tsai et al., "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma", Nature, vol. 467, no. 7315, pp. 596-599, 2010.
75. E. W. Joseph, C. A. Pratilas, P. I. Poulikakos et al., "The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner", Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14903-14908, 2010.
76. P. Salerno, V. De Falco, A. Tamburrino et al., "Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 450-455, 2010.
77. E. Sala, L. Mologni, S. Truffa, C. Gaetano, G. E. Bollag, and C. Gambacorti-Passerini, "BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells", Molecular Cancer Research, vol. 6, no. 5, pp. 751-759, 2008.
78. J. N. Søndergaard, R. Nazarian, Q. Wang et al., "Differential sensitivity of melanoma cell lines with BRAFV600Emutation to the specific Raf inhibitor PLX4032", Journal of Translational Medicine, vol. 8, article 39, 2010.
79. K. T. Flaherty, I. Puzanov, K. B. Kim et al., "Inhibition of mutated, activated BRAF in metastatic melanoma", New England Journal of Medicine, vol. 363, no. 9, pp. 809-819, 2010.
80. G. K. Schwartz, S. Robertson, A. Shen et al., "A Phase I study of XL281, a selective oral RAF kinase inhibitor, in patients with advanced solid tumors", Journal of Clinical Oncology, vol. 27, no. 15s, abstract 3513, 2009.
81. D. W. Kim, Y. S. Jo, H. S. Jung et al., "An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases", Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 4070-4076, 2006. (Pubitemid 44536887)
82. E. E. W. Cohen, B. M. Needles, K. J. Cullen et al., "Phase II study of sunitinib in refractory thyroid cancer", Journal of Clinical Oncology, vol. 26, abstract 6025, 2008.
83. M. J. Bugalho, R. Domingues, and A. Borges, "A case of advanced medullary thyroid carcinoma successfully treated with sunitinib", Oncologist, vol. 14, no. 11, pp. 1083-1087, 2009.
84. D. Mannavola, P. Coco, G. Vannucchi et al., "A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake", Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 9, pp. 3531-3534, 2007. (Pubitemid 47435331)
85. E. Wong, L. S. Rosen, M. Mulay et al., "Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity", Thyroid, vol. 17, no. 4, pp. 351-355, 2007. (Pubitemid 46776140)
86. M. B. Bass, S. I. Sherman, M. J. Schlumberger et al., "Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 11, pp. 5018-5027, 2010.
87. V. Baldazzi, R. Tassi, A. Lapini, C. Santomaggio, M. Carini, and R. Mazzanti, "The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study", Urologic Oncology: Seminars and Original Investigations. In press.
88. M. Schmidinger, U. M. Vogl, M. Bojic et al., "Hypothyroidism in patients with renal cell carcinoma: blessing or curse?" Cancer, vol. 117, no. 3, pp. 534-544, 2011.
89. T. F. Chu, M. A. Rupnick, R. Kerkela et al., "Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib", Lancet, vol. 370, no. 9604, pp. 2011-2019, 2007. (Pubitemid 350236338)
90. B. B. Hasinoff and D. Patel, "The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro", Toxicology and Applied Pharmacology, vol. 249, no. 2, pp. 132-139, 2010.
91. M. H. Chen, R. Kerkelä, and T. Force, "Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics", Circulation, vol. 118, no. 1, pp. 84-95, 2008.
92. S. R. Wedge, D. J. Ogilvie, M. Dukes et al., "ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration", Cancer Research, vol. 62, no. 16, pp. 4645-4655, 2002.
93. F. Ciardiello, R. Caputo, V. Damiano et al., "Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase", Clinical Cancer Research, vol. 9, no. 4, pp. 1546-1556, 2003. (Pubitemid 36418413)
94. R. S. Herbst, J. V. Heymach, M. S. O'Reilly, A. Onn, and A. J. Ryan, "Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis", Expert Opinion on Investigational Drugs, vol. 16, no. 2, pp. 239-249, 2007. (Pubitemid 46206638)
95. F. Carlomagno, D. Vitagliano, T. Guida et al., "ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases", Cancer Research, vol. 62, no. 24, pp. 7284-7290, 2002. (Pubitemid 36025251)
96. D. Vitagliano, V. De Falco, A. Tamburrino et al., "The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells", Endocrine-Related Cancer, vol. 18, no. 1, pp. 1-11, 2011.
97. S. A. Wells Jr., J. E. Gosnell, R. F. Gagel et al., "Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer", Journal of Clinical Oncology, vol. 28, no. 5, pp. 767-772, 2010.
98. "FDA Briefing Document Oncologic Drugs Advisory Committee Meeting", December 2010, http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM235086.pdf.
99. B. G. Robinson, L. Paz-Ares, A. Krebs, J. Vasselli, and R. Haddad, "Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2664-2671, 2010.
100. United States Food and Drug Administration Press Release, "FDA approves new treatment for rare form of thyroid cancer", April 2011, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.htm.
101. M. Carroll, S. Ohno-Jones, S. Tamura et al., "CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins", Blood, vol. 90, no. 12, pp. 4947-4952, 1997. (Pubitemid 28007210)
102. A. Podtcheko, A. Ohtsuru, S. Tsuda et al., "The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 4, pp. 1889-1896, 2003. (Pubitemid 36623419)
103. J. M. Dziba and K. B. Ain, "Imatinib mesylate (Gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro", Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2127-2135, 2004. (Pubitemid 38619841)
104. J. W. B. De Groot, B. A. Zonnenberg, P. Q. Van Ufford-Mannesse et al., "A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma", Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 9, pp. 3466-3469, 2007. (Pubitemid 47435321)
105. K. Frank-Raue, M. Fabel, S. Delorme, U. Haberkorn, and F. Raue, "Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma", European Journal of Endocrinology, vol. 157, no. 2, pp. 215-220, 2007. (Pubitemid 47233127)
106. A. K. Samadi, R. Mukerji, A. Shah, B. N. Timmermann, and M. S. Cohen, "A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo", Surgery, vol. 148, no. 6, pp. 1228-1236, 2010.
107. R. Kumar, V. B. Knick, S. K. Rudolph et al., "Pharmacokinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity", Molecular Cancer Therapeutics, vol. 6, no. 7, pp. 2012-2021, 2007. (Pubitemid 47052491)
108. B. Gril, D. Palmieri, Y. Qian et al., "Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis", Clinical Cancer Research, vol. 17, no. 1, pp. 142-153, 2011.
109. M. Friedlander, K. C. Hancock, D. Rischin et al., "A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer", Gynecologic Oncology, vol. 119, no. 1, pp. 32-37, 2010.
110. N. Altorki, M. E. Lane, T. Bauer et al., "Phase II proof-of concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer", Journal of Clinical Oncology, vol. 28, no. 19, pp. 3131-3137, 2010.
111. J. E. Ward and W. M. Stadler, "Pazopanib in renal cell carcinoma", Clinical Cancer Research, vol. 16, no. 24, pp. 5923-5927, 2010.
112. K. C. Bible, V. J. Suman, J. R. Molina et al., "Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study", The Lancet Oncology, vol. 11, no. 10, pp. 962-972, 2010.
113. A. Polverino, A. Coxon, C. Starnes et al., "AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts", Cancer Research, vol. 66, no. 17, pp. 8715-8721, 2006. (Pubitemid 44449188)
114. L. S. Rosen, R. Kurzrock, M. Mulay et al., "Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors", Journal of Clinical Oncology, vol. 25, no. 17, pp. 2369-2376, 2007. (Pubitemid 46999207)
115. S. I. Sherman, L. J. Wirth, J. P. Droz et al., "Motesanib diphosphate in progressive differentiated thyroid cancer", New England Journal of Medicine, vol. 359, no. 1, pp. 31-42, 2008. (Pubitemid 351931094)
116. M. J. Schlumberger, R. Elisei, L. Bastholt et al., "Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer", Journal of Clinical Oncology, vol. 27, no. 23, pp. 3794-3801, 2009.
117. M. B. Bass, S. I. Sherman, M. J. Schlumberger et al., "Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 11, pp. 5018-5027, 2010.
118. H. S. Rugo, R. S. Herbst, G. Liu et al., "Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results", Journal of Clinical Oncology, vol. 23, no. 24, pp. 5474-5483, 2005.
119. E. E. W. Cohen, L. S. Rosen, E. E. Vokes et al., "Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study", Journal of Clinical Oncology, vol. 26, no. 29, pp. 4708-4713, 2008.
120. R. Mineo, A. Costantino, F. Frasca et al., "Activation of the Hepatocyte Growth Factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels", Endocrinology, vol. 145, no. 9, pp. 4355-4365, 2004. (Pubitemid 39120585)
121. R. Kurzrock, S. Sherman, D. Hong et al., "A Phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients with advanced malignancies, including a subgroup of patients with medullary thyroid carcinoma", in the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, October 2008, poster number 379.
122. A. Antonelli, G. Bocci, C. La Motta et al., "Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. E288-E296, 2011.
123. N. A. Pennell, G. H. Daniels, R. I. Haddad et al., "A phase II study of gefitinib in patients with advanced thyroid cancer", Thyroid, vol. 18, no. 3, pp. 317-323, 2008. (Pubitemid 351415790)
124. S. I. Sherman, "Targeted therapy of thyroid cancer", Biochemical Pharmacology, vol. 80, no. 5, pp. 592-601, 2010.
125. J. A. Fagin, R. M. Tuttle, and D. G. Pfister, "Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2621-2624, 2010.
126. F. Furuya, H. Shimura, H. Suzuki et al., "Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin", Endocrinology, vol. 145, no. 6, pp. 2865-2875, 2004. (Pubitemid 38686236)
127. J. A. Woyach, R. T. Kloos, M. D. Ringel et al., "Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with
128. F. Furuya, H. Shimura, H. Suzuki et al., "Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin", Endocrinology, vol. 145, no. 6, pp. 2865-2875, 2004. (Pubitemid 38686236)
129. P. Hou, E. Bojdani, and M. Xing, "Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 2, pp. 820-828, 2010.
130. G. Vitale, P. Tagliaferri, M. Caraglia et al., "Slow release lanreotide in combination with interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma", Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 983-988, 2000. (Pubitemid 32269337)
131. T. Bachleitner-Hofmann, J. Friedl, M. Hassler et al., "Pilot trial of autologous dendritic cells loaded with tumor lysate (s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma", Oncology Reports, vol. 21, no. 6, pp. 1585-1592, 2009.
132. R. D. Blumenthal and D. M. Goldenberg, "Methods and goals for the use of in vitro and in vivo chemosensitivity testing", Molecular Biotechnology, vol. 35, no. 2, pp. 185-197, 2007. (Pubitemid 46631888)
133. T. J. Kruser, D. L. Wheeler, E. A. Armstrong et al., "Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors", Clinical Cancer Research, vol. 16, no. 14, pp. 3639-3647, 2010.